NASDAQ:TBIO

Translate Bio Competitors

$18.93
-0.75 (-3.81 %)
(As of 04/16/2021 11:00 AM ET)
Add
Compare
Today's Range
$18.66
Now: $18.93
$19.70
50-Day Range
$16.00
MA: $19.68
$25.70
52-Week Range
$9.64
Now: $18.93
$34.64
Volume16,259 shs
Average Volume1.22 million shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.96

Competitors

Translate Bio (NASDAQ:TBIO) Vs. KOD, VIR, CBPO, ALLO, BEAM, and IOVA

Should you be buying TBIO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Translate Bio, including Kodiak Sciences (KOD), Vir Biotechnology (VIR), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Beam Therapeutics (BEAM), and Iovance Biotherapeutics (IOVA).

Kodiak Sciences (NASDAQ:KOD) and Translate Bio (NASDAQ:TBIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Institutional and Insider Ownership

82.3% of Kodiak Sciences shares are held by institutional investors. Comparatively, 92.9% of Translate Bio shares are held by institutional investors. 39.3% of Kodiak Sciences shares are held by company insiders. Comparatively, 12.3% of Translate Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Kodiak Sciences and Translate Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
Translate Bio-70.38%-27.54%-12.82%

Risk and Volatility

Kodiak Sciences has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Translate Bio has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Kodiak Sciences and Translate Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences17402.25
Translate Bio04702.64

Kodiak Sciences presently has a consensus target price of $129.9091, suggesting a potential upside of 14.39%. Translate Bio has a consensus target price of $25.70, suggesting a potential upside of 35.76%. Given Translate Bio's stronger consensus rating and higher possible upside, analysts clearly believe Translate Bio is more favorable than Kodiak Sciences.

Earnings & Valuation

This table compares Kodiak Sciences and Translate Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-90.86
Translate Bio$7.80 million182.53$-113,290,000.00($1.84)-10.29

Kodiak Sciences has higher earnings, but lower revenue than Translate Bio. Kodiak Sciences is trading at a lower price-to-earnings ratio than Translate Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Translate Bio beats Kodiak Sciences on 8 of the 13 factors compared between the two stocks.

Translate Bio (NASDAQ:TBIO) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Translate Bio and Vir Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Translate Bio-70.38%-27.54%-12.82%
Vir Biotechnology-339.61%-47.11%-39.44%

Volatility & Risk

Translate Bio has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of -0.99, indicating that its stock price is 199% less volatile than the S&P 500.

Institutional and Insider Ownership

92.9% of Translate Bio shares are held by institutional investors. Comparatively, 54.5% of Vir Biotechnology shares are held by institutional investors. 12.3% of Translate Bio shares are held by company insiders. Comparatively, 37.2% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Translate Bio and Vir Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Translate Bio$7.80 million182.53$-113,290,000.00($1.84)-10.29
Vir Biotechnology$8.09 million726.46$-174,680,000.00($5.76)-7.97

Translate Bio has higher earnings, but lower revenue than Vir Biotechnology. Translate Bio is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Translate Bio and Vir Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Translate Bio04702.64
Vir Biotechnology20502.43

Translate Bio presently has a consensus price target of $25.70, suggesting a potential upside of 35.76%. Vir Biotechnology has a consensus price target of $66.00, suggesting a potential upside of 43.73%. Given Vir Biotechnology's higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Translate Bio.

Summary

Translate Bio beats Vir Biotechnology on 10 of the 14 factors compared between the two stocks.

Translate Bio (NASDAQ:TBIO) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Translate Bio and China Biologic Products, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Translate Bio04702.64
China Biologic Products0000N/A

Translate Bio currently has a consensus price target of $25.70, suggesting a potential upside of 35.76%. Given Translate Bio's higher possible upside, analysts plainly believe Translate Bio is more favorable than China Biologic Products.

Institutional & Insider Ownership

92.9% of Translate Bio shares are owned by institutional investors. Comparatively, 34.8% of China Biologic Products shares are owned by institutional investors. 12.3% of Translate Bio shares are owned by insiders. Comparatively, 2.7% of China Biologic Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Translate Bio has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Profitability

This table compares Translate Bio and China Biologic Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Translate Bio-70.38%-27.54%-12.82%
China Biologic Products27.43%8.32%7.64%

Earnings & Valuation

This table compares Translate Bio and China Biologic Products' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Translate Bio$7.80 million182.53$-113,290,000.00($1.84)-10.29
China Biologic Products$503.70 million9.24$138.81 million$4.2827.63

China Biologic Products has higher revenue and earnings than Translate Bio. Translate Bio is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Summary

China Biologic Products beats Translate Bio on 7 of the 13 factors compared between the two stocks.

Translate Bio (NASDAQ:TBIO) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Institutional & Insider Ownership

92.9% of Translate Bio shares are owned by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are owned by institutional investors. 12.3% of Translate Bio shares are owned by company insiders. Comparatively, 31.3% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Translate Bio and Allogene Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Translate Bio$7.80 million182.53$-113,290,000.00($1.84)-10.29
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-17.73

Translate Bio has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Translate Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Translate Bio has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.

Profitability

This table compares Translate Bio and Allogene Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Translate Bio-70.38%-27.54%-12.82%
Allogene TherapeuticsN/A-27.59%-24.97%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Translate Bio and Allogene Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Translate Bio04702.64
Allogene Therapeutics031302.81

Translate Bio presently has a consensus price target of $25.70, suggesting a potential upside of 35.76%. Allogene Therapeutics has a consensus price target of $52.0833, suggesting a potential upside of 60.55%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Translate Bio.

Summary

Allogene Therapeutics beats Translate Bio on 8 of the 13 factors compared between the two stocks.

Beam Therapeutics (NASDAQ:BEAM) and Translate Bio (NASDAQ:TBIO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Translate Bio shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by insiders. Comparatively, 12.3% of Translate Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Beam Therapeutics and Translate Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$20,000.00228,577.73$-78,330,000.00($14.05)-5.21
Translate Bio$7.80 million182.53$-113,290,000.00($1.84)-10.29

Beam Therapeutics has higher earnings, but lower revenue than Translate Bio. Translate Bio is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Beam Therapeutics and Translate Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beam Therapeutics-529,075.00%-103.41%-48.05%
Translate Bio-70.38%-27.54%-12.82%

Analyst Recommendations

This is a summary of recent ratings and price targets for Beam Therapeutics and Translate Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beam Therapeutics03302.50
Translate Bio04702.64

Beam Therapeutics currently has a consensus target price of $96.00, suggesting a potential upside of 31.18%. Translate Bio has a consensus target price of $25.70, suggesting a potential upside of 35.76%. Given Translate Bio's stronger consensus rating and higher probable upside, analysts clearly believe Translate Bio is more favorable than Beam Therapeutics.

Summary

Translate Bio beats Beam Therapeutics on 10 of the 13 factors compared between the two stocks.

Iovance Biotherapeutics (NASDAQ:IOVA) and Translate Bio (NASDAQ:TBIO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Profitability

This table compares Iovance Biotherapeutics and Translate Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iovance BiotherapeuticsN/A-50.64%-45.64%
Translate Bio-70.38%-27.54%-12.82%

Valuation & Earnings

This table compares Iovance Biotherapeutics and Translate Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-19.26
Translate Bio$7.80 million182.53$-113,290,000.00($1.84)-10.29

Translate Bio has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Translate Bio, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

94.6% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 92.9% of Translate Bio shares are held by institutional investors. 9.9% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 12.3% of Translate Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Iovance Biotherapeutics and Translate Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iovance Biotherapeutics011002.91
Translate Bio04702.64

Iovance Biotherapeutics currently has a consensus target price of $50.50, suggesting a potential upside of 64.87%. Translate Bio has a consensus target price of $25.70, suggesting a potential upside of 35.76%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than Translate Bio.

Volatility & Risk

Iovance Biotherapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Translate Bio has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Summary

Iovance Biotherapeutics beats Translate Bio on 7 of the 13 factors compared between the two stocks.


Translate Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$113.57-1.9%$5.92 billionN/A-48.95
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$45.92-1.9%$5.76 billion$8.09 million-19.46Analyst Downgrade
Insider Selling
News Coverage
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.26-0.2%$4.65 billion$503.70 million33.03
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.44-1.3%$4.62 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.18-0.8%$4.61 billion$20,000.00-5.21
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.63-0.7%$4.47 billionN/A-15.95Analyst Report
Increase in Short Interest
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$71.44-3.0%$3.60 billionN/A-41.06Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$71.87-3.2%$3.31 billion$125.57 million-42.03Insider Selling
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.39-4.1%$3.05 billionN/A0.00News Coverage
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$39.41-0.8%$2.87 billion$50.04 million0.00
Editas Medicine logo
EDIT
Editas Medicine
1.6$35.35-15.9%$2.76 billion$20.53 million-20.32Analyst Report
Gap Up
Vericel logo
VCEL
Vericel
1.1$57.65-0.6%$2.67 billion$117.85 million-5,765,000.00Increase in Short Interest
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.36-1.1%$2.09 billion$31.43 million-5.04Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.16-1.6%$2.01 billion$48.83 million-14.68Analyst Report
bluebird bio logo
BLUE
bluebird bio
1.8$28.94-2.7%$2.00 billion$44.67 million-2.64
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.85-0.8%$1.95 billionN/A-11.14Decrease in Short Interest
Gap Up
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.50-0.2%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$76.36-0.3%$1.70 billionN/A-51.59
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.39-3.3%$1.69 billion$102.43 million-18.98
Immunovant logo
IMVT
Immunovant
1.8$15.58-1.9%$1.56 billionN/A-12.08Increase in Short Interest
News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.38-4.3%$1.52 billion$35.23 million-13.86Increase in Short Interest
AlloVir logo
ALVR
AlloVir
1.4$22.18-1.9%$1.47 billionN/A0.00Increase in Short Interest
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.08-2.6%$1.42 billionN/A0.00Increase in Short Interest
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.55-6.7%$1.34 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.78-0.4%$1.06 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.34-0.7%$1.04 billion$356.07 million7.03
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.41-5.9%$1.00 billionN/A0.00Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.00-6.8%$979.79 million$42.74 million-222.22Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$24.53-1.5%$940.63 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Passage Bio logo
PASG
Passage Bio
1.8$16.16-6.4%$925.89 millionN/A0.00Increase in Short Interest
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.77-7.2%$919.28 million$250,000.00-6.91Analyst Upgrade
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.01-0.8%$911.40 millionN/A-4.13Insider Selling
Increase in Short Interest
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.68-1.4%$840.75 million$69.89 million-4.22
Cellectis logo
CLLS
Cellectis
1.3$19.13-0.9%$825.65 million$22.99 million-10.18
Inhibrx logo
INBX
Inhibrx
1.6$19.89-5.5%$791.95 millionN/A0.00Decrease in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.15-3.1%$784.23 million$2.51 million-3.73
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.89-3.1%$783.55 million$1.12 million-4.94Increase in Short Interest
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.11-2.3%$686.71 million$14.75 million-2.62Increase in Short Interest
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$19.90-1.8%$656.65 million$5.78 million-9.34Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.23-3.8%$638.89 million$9.86 million-8.86
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.